What Лейкоген Treats: Main Uses and Benefits

Лейкоген is applied in clinical settings that involve low blood cell counts. The medication is commonly used in patients who have undergone treatments such as chemotherapy or radiation therapy, which may lead to myelosuppression, resulting in severe leukopenia (low white blood cells) and thrombocytopenia (low platelets). This application is associated with managing conditions that involve a heightened systemic burden.

This may assist with the recovery of blood counts, which supports functional stability and helps improve day-to-day comfort during symptomatic periods. The primary role is relevant for easing symptoms related to a compromised immune response and low platelet counts, and it supports the patient during difficult episodes by easing the overall symptom burden.

---

Quick Fact: Relief for Systemic Imbalance

Domain	Benefit	Context
Symptom Clusters	Helps address symptoms that create noticeable physiological strain and functional instability.
Condition Categories	Relevant in conditions presenting with systemic imbalance due to low blood cell counts.
Patient Benefit	Contributes to improved comfort and assists with maintaining functional stability during symptomatic periods.

Who Can and Cannot Use Лейкоген?

The eligibility for using Лейкоген (Leucogen) is defined by specific criteria in official regulatory documentation, which primarily focus on absolute contraindications and established use in various age groups.

Who Must Not Use (Contraindications)

Individuals are formally contraindicated and must not use Лейкоген if they meet the following criteria, as stated in the prescribing information:

• Hypersensitivity: A known allergy or severe reaction to the active ingredient, Chloramine T, or any other component of the tablet formulation.
• Specific Blood Malignancies: A diagnosis of Lymphogranulomatosis (a form of lymphoma) or other Malignant Diseases of the Hematopoietic Organs (Hemoblastoses).

---

Established Eligibility

The medicine's use is officially established across a wide patient population:

Population Group	Regulatory Status
Adults	Established use.
Children	Established, including use in infants (dosing provided across the pediatric age spectrum).
Pregnancy/Lactation	No explicit status (permitted, restricted, or prohibited) is formally documented in the primary regulatory labeling.
Organ Impairment	No explicit, official restrictions are stated for use in patients with severe hepatic or renal impairment.

Eligibility is primarily determined by the absence of contraindications, as the medicine's use is sanctioned for all age groups in the regulated market.

Interactions with other medicines and products

Official regulatory documentation structures the interaction profile of this product around constraints related to the concurrent use of other immunological products.

Interaction Constraints Summary

The primary constraint pertains to timing-based separation from most other vaccines. Safety and efficacy data are generally not available for concurrent use with other immunological products, with the exception of one specific, pre-authorized combination (Feligen RCP).

Interaction Type	Official Regulatory Statement	Constraint Type
Other Vaccines	Do not administer other vaccines within 14 days before or after the administration of this product.	Timing Restriction
Specific Products	Co-administration is permissible only with the officially specified immunological product.	Use-With-Caution

Interaction-Related Restrictions

There is a strict regulatory recommendation that no other non-specified vaccine should be administered within the 14-day period surrounding the use of this product. This establishes a required temporal separation to avoid potential compromises in the effectiveness or safety profile of the vaccination sequence. The overall profile is therefore defined by procedural, immunological constraints rather than pharmacokinetic interactions (e.g., CYP enzyme or transporter-mediated effects).

The mechanism of Лейкоген (Chloramine T) is characterized by direct chemical interaction to induce leukopoiesis (white blood cell production). It does not rely on binding to classical pharmacological receptors but acts by modifying key cellular processes in the bone marrow.

Chemical Activation of Hematopoietic Progenitors

The drug initiates its effect by acting as a source of reactive chlorine to chemically modify proteins on or within myeloid progenitor cells located centrally in the bone marrow. This non-receptor-mediated interaction serves as a potent proliferative stress signal, bypassing standard regulatory pathways to accelerate cell development. This chemical activation domain is the core mechanism that initiates the subsequent production cycle.

Upregulation of the Myelopoiesis Pathway

Following activation, the drug enhances the leukopoietic pathway, specifically increasing the rate of proliferation (division) and differentiation (maturation) of the white blood cell precursor cells. This sustained acceleration of the production cycle results in an increased release of mature granulocytes from the bone marrow. This physiological effect leads to an increase in the circulating leukocyte count.

Mechanism-Constrained Onset Kinetics

The final increase in the leukocyte count is functionally constrained by the natural cellular kinetics required for new cells to mature. Unlike drugs that cause rapid receptor blockade, the mechanism’s output is dependent on the time needed for cell division and maturation, resulting in a gradual, sustained change in cellular kinetics rather than an acute reaction.

Лейкоген is an orally administered medication that is consistently supplied in a tablet form, with the official single unit dose established at 20 mg (0.02 g). The approved administration method is strictly oral.

Standardized Dosing and Frequency

The standard adult usage pattern dictates taking the tablet 3 to 4 times per day. This frequent administration results in a defined total daily intake typically ranging from 60 mg to 80 mg (0.06 g to 0.08 g), as outlined in the official prescribing summary. No specific instructions regarding administration in relation to meals or other preparation requirements are detailed in the regulatory information.

Course Duration and Cyclic Protocol

The typical duration for a single treatment course is fixed at 10 days. The official protocol allows for an extended administration period of up to 2–4 weeks when managing persistent requirements. Use of the drug is governed by a mandatory cyclic pattern: a specific rest interval of 1.5 to 2 weeks must be observed following the completion of one course before a repeat course can be initiated.

Age-Group Administration Rules

The drug’s official instructions mandate a precise, age-dependent dosing schedule for all pediatric patients, ensuring regulated use across different age cohorts:

Age Group	Total Daily Dose
Over 7 years	60 mg (0.06 g)
Up to 7 years	40 mg (0.04 g)
6 months to 1 year	20 mg (0.02 g)
Up to 6 months	10 mg (0.01 g)

The administration route remains oral for all groups, consistent with the tablet formulation.

Research Evidence / Overview of Studies for Лейкоген

---

Evidence for use in Conditions Involving Low White Blood Cell Counts

Research has explored the use of Лейкоген in conditions characterized by fluctuating or episodic manifestations where the body’s white blood cell count becomes abnormally low. These conditions involving low white blood cell counts (leukopenia) or a severe lack of certain white blood cells (agranulocytosis) was studied for its association with these numbers. The primary measurements that studies monitored were changes in white blood cell and neutrophil counts over defined time intervals.

Studies of Лейкоген for Agranulocytosis

Clinical research examined how Лейкоген was observed in individuals with agranulocytosis. These studies monitored changes in blood cell counts, specifically looking for fluctuations in these counts during the short-term symptom changes that occur following administration. Findings describe patterns observed in the studies where changes in these counts were observed in some studies during the study period.

Studies of Лейкоген for Leukopenia

Lейкоген was also evaluated in people with the broader condition of leukopenia, an overall low white blood cell count. Studies explored whether the compound was associated with changes in the total white blood cell count. Data show patterns related to fluctuations in these counts, often measured as outcomes describing episodic or acute changes in the bloodwork.

---

Long-term Studies and Follow-up

Research concerning the long-term effects are not fully established for Лейкоген. Studies that have monitored results over extended periods following the initial use are generally limited. The available follow-up durations were limited, making it difficult to fully assess the durability of changes—meaning how long the white blood cell count may remain at a stable level after the initial acute phase. This highlights that there is limited information for long-term results.

---

Evidence in Special Populations

Evidence is limited regarding the use of Лейкоген in various special populations. Research was evaluated in a general adult population, but data for certain groups remain insufficient. For instance, studies on children are scarce, and the evidence base for older adults with existing health concerns is not robust. Comparative evidence is lacking to show if the observed patterns differ significantly in these populations.

---

What is Still Uncertain about Лейкоген

The evidence gathered to date provides important context, but several key questions remain. The main evidence gaps include a lack of large, well-controlled comparative studies that can definitively establish the consistency of the findings. Furthermore, findings were mixed in some of the research exploring short-term symptom changes, and the interpretation of these results can be challenging. The long-term effects are not fully established, and evidence highlights what is known — and what is still uncertain.

Key Studies & References

1. A Multi-center, Randomized, Double-blind, Phase III Clinical Trial of Leucogen Versus Placebo on Leukocyte and Platelet Whole-course Management Assisted by PFLL Chemotherapy in the Treatment of Stage IV, Recurrent or Metastatic NPC (NCT05780294)
2. Clinical Study on the Treatment of Leukopenia after Chemotherapy with Leucogen Tablets and Shengbai Mixture

Common questions about Лейкоген (FAQ)

Q: What is Лейкоген used for?

A: Лейкоген is a medication that has been studied in the context of certain blood cell disorders, including leukopenia (a low white blood cell count). It belongs to a group of compounds that have been investigated for their potential impact on bone marrow function.

Q: How does Лейкоген work in the body?

A: Research suggests that Лейкоген may interact with metabolic processes within the bone marrow. Evidence indicates it is a pyrimidine derivative, which means it may be involved in nucleic acid synthesis. The precise mechanism of how this action relates to the studied clinical effects is still a subject of ongoing research.

Q: What are the possible side effects of Лейкоген?

A: Clinical trials and post-marketing surveillance have identified several commonly reported adverse events. These may include gastrointestinal disturbances such as nausea, vomiting, or diarrhea, as well as allergic reactions. Patients should consult a healthcare professional regarding any adverse effects they experience during treatment.

Q: Can Лейкоген be taken with food?

A: The information available in regulatory documents typically provides guidance on administration. Generally, it has been described as being taken orally. Consult the prescribing information or a pharmacist for specific administration guidelines related to food consumption, as this can vary by formulation.

Q: Is Лейкоген the same as other drugs for leukopenia?

A: Лейкоген is a unique chemical entity (a pyrimidine derivative). While other treatments for leukopenia exist, such as colony-stimulating factors (CSFs), it operates through a distinct pathway. Comparative studies are generally needed to evaluate whether one approach is preferred over another for a specific patient population.

Storage and Disposal of Лейкоген

Official regulations require specific conditions for storing and disposing of Лейкоген (Chloramine T tablets) to maintain product stability.

Storage Requirements

The medicine must be stored in a cool and dry place, ensuring temperatures do not exceed 40 C. The container must be kept tightly closed and protected from light and moisture to prevent decomposition. For safety, the product must be stored locked up and out of the reach of children. Storage near acids is strictly prohibited to avoid hazardous chemical reactions.

Disposal Instructions

Unused or expired product must be disposed of according to local regulations for controlled waste. Disposal into household waste, drains, surface water, or soil is forbidden to prevent environmental contamination.